Homology Medicines
FIXXHomology Medicines, Inc. (NASDAQ: FIXX) was a clinical-stage genetic medicines company based in the United States. The company's business focus was on the research and development of treatments for rare genetic diseases. It employed two proprietary technology platforms: gene therapy to deliver functional copies of genes and gene editing to directly correct mutations at the DNA level. This approach aimed to address the root cause of diseases with a single administration. The company's pipeline included product candidates targeting rare disorders with significant unmet medical need. Its lead clinical programs were HMI-102, an investigational gene therapy for adults with phenylketonuria (PKU), and HMI-103, a gene editing candidate for pediatric patients with PKU. Homology Medicines also had preclinical programs in other conditions, including Hunter syndrome and metachromatic leukodystrophy. In March 2024, Homology Medicines announced a strategic shift, discontinuing its clinical development programs and reducing its workforce. The company stated its intent to explore strategic alternatives for its intellectual property and platform technologies, including its nuclease-free gene editing and gene therapy vectors derived from human adeno-associated viruses (AAVs).
About
Homology Medicines, Inc. (NASDAQ: FIXX) was a clinical-stage genetic medicines company based in the United States. The company's business focus was on the research and development of treatments for rare genetic diseases. It employed two proprietary technology platforms: gene therapy to deliver functional copies of genes and gene editing to directly correct mutations at the DNA level. This approach aimed to address the root cause of diseases with a single administration. The company's pipeline included product candidates targeting rare disorders with significant unmet medical need. Its lead clinical programs were HMI-102, an investigational gene therapy for adults with phenylketonuria (PKU), and HMI-103, a gene editing candidate for pediatric patients with PKU. Homology Medicines also had preclinical programs in other conditions, including Hunter syndrome and metachromatic leukodystrophy. In March 2024, Homology Medicines announced a strategic shift, discontinuing its clinical development programs and reducing its workforce. The company stated its intent to explore strategic alternatives for its intellectual property and platform technologies, including its nuclease-free gene editing and gene therapy vectors derived from human adeno-associated viruses (AAVs).